Evaluate
Research Company/Group
We believe that connected data leads to a clearer picture. We help clients can make accurate, high value decisions that ensure therapies get to the patients faster. Our seamless view of the industry builds your understanding of the commercial issues that affect strategic decisions — so you can turn understanding into insight, and insight into action.
From market sizing and commercial opportunity assessment, to competitive intelligence and deal benchmarking, Evaluate is here to help. Our insights solutions put the data you need at your fingertips, while our experts are here to deliver tailored guidance.
Evaluate is proud to be part of Norstella – an organisation that unites five market-leading companies with a shared goal: to improve patient access to life-changing therapies. We are stronger together – and as Norstella company, Evaluate plays a key role in helping you connect the dots from pipeline to patient. Source
Actions
Media Outlet details
| Scope | International, Trade/B2B |
|---|---|
| Language | English |
| Country | United Kingdom |
Similarweb UVM
|
Request pricing |
Comscore UVM
|
Request pricing |
Recent Articles
Search ArticlesEvaluate Leaders Forum | London
This is an invitation-only event for senior professionals in business development, finance, and forecasting. A speaker announcement will follow shortly. In the meantime, to register your interest, RSVP today.
Why Your LBE Keeps Drifting From the Plan
Your Latest Best Estimate (LBE) forecast is the perfect partner to your Annual Operating Plan (AOP). Well, they are perfect partners when they work together effectively, which isn’t always – or even usually – the case. To learn more about what teams get wrong and how they can get their LBEs and AOPs working together in harmony, I spoke to Ufuk Ezer, Director, Implementation at J+D Forecasting, who works with pharmaceutical and biotech companies on LBE process design.
Turning R&D Benchmarks into Competitor Signals: What We’re Bringing to Pharma CI
Evaluate is at Pharma CI 2026 in Newark, New Jersey, on 16 and 17 September, talking agentic AI, turning R&D benchmarks into competitor signals, and our new competitive intelligence agent, Atlas CI. Pharma CI is just around the corner again – it seems to come around quicker every year! The Evaluate team is heading to Newark and we’re looking forward to spending a few days in the company of pharma competitive intelligence (CI) teams to discuss all the big topics on their minds.
Designing Pharmaceutical Forecast Models That Actually Work
Skip to content Every big – and expensive – decision that’s made in biopharma is built on a forecast. From launch decisions to portfolio prioritization and investment planning, to strategic direction – everything uses input from a pharmaceutical forecast model. Yet model design is often where things go wrong. A model that is poorly designed does not just produce a bad number, it undermines the credibility of every decision built on top of it, which ultimately impacts the patient.
What are you Getting Wrong in your Annual Operating Plan?
Skip to content Senior Director, Content & Thought Leadership Marketing Published Senior Director, Content & Thought Leadership Marketing Published The Annual Operating Plan (AOP) and the Latest Best Estimate (LBE) are two of the most important forecasting processes a biotech or pharma commercial team runs. They are also among the most misunderstood, usually over how the two should work together.
Oncology Dealmaking is Becoming More Surgical
Oncology remains the largest segment in global pharma, accounting for around $241bn in 2025 prescription drug revenues. But portfolio momentum is fragmenting, and the next growth cycle looks materially different from the last one. We address many of the big issues in the oncology space in the new Evaluate Spotlight episode which is available here. The past five years were largely built on checkpoint inhibitors and established biologics, but that era is closing.
What Good Forecast Model Design Actually Looks Like
Drawing on the expertise of J+D Forecasting, this article examines forecast model design: how to build a model that supports decision-making across the full planning cycle, and the design failures that undermine even technically capable forecasting functions.
What Good LBE Forecasting Actually Looks Like
Skip to content The Latest Best Estimate keeps a commercial plan honest through the year. From how to define the right LBE cadence, to making risk and opportunities explicit in your forecasting, this article sets out what good LBE practice looks like and where it most commonly goes wrong. I would like to receive Evaluate industry & market reports, and the latest news from Evaluate.
The Use of AI in Pharmaceutical Commercialization: Insights from the Field
Skip to content AI adoption in pharmaceutical commercialization is accelerating but results are uneven, confidence is often misplaced, and most teams are using tools that were never built for the decisions they’re making. This report brings together survey data from 150 senior biopharma executives to give the clearest picture yet of where the industry stands and what it will take to get AI right across forecasting, competitive intelligence, dealmaking and portfolio strategy.
The Use of AI in Pharmaceutical Commercialization Infographic
Skip to content Most commercial pharma teams are running AI experiments and almost none are getting results they can stake a real decision on. This infographic draws on exclusive survey data from 150 senior biopharma executives, fielded by Evaluate in partnership with BioPharma Dive to show where the industry stands on AI adoption, why the tool gap is a growing business risk, and what purpose-built AI intelligence looks like in practice.